Table 1: Cytotoxicity and antiviral activity of derivatives 4a,b,c,d-7a,b,c,d against CV-B5 and Sb-1. Data represent mean values of three independent determinations. Pleconaril was used as a positive control.

Compounds Vero76 CV-B5 Sb-1 Ref.
- aCC50 bEC50 - -
4a 60 >60 42 [15]
4b >100 >100 >100 [15]
4c >100 42 19 -
4d >100 >100 >100 [16]
5a 71 28 >71 [15]
5b >100 >100 >100 [15]
5c >100 41 50 -
5d >100 >100 >100 [16]
6a >100 30 47 [15]
6b >100 10 >100 [15]
6c >100 11 37 -
6d >100 >100 >100 [16]
7a >100 >100 >100 [15]
7b >100 30 53 [15]
7c >100 10.2 3.8 -
7d >100 >100 >100 [16]
Ref. compounds - - - -
Pleconaril 77±6.8 0.005±0.002 2±0.6 -

aCompound concentration (µM) required to reduce the viability of mock-infected Vero76 monolayers by 50%. bCompound concentration (µM) required to reduce the plaque number of the indicated virus by 50% in Vero76 monolayers.